Mayo Clinic is participating in the first in-human investigation of regenerative therapy for the treatment of drug-resistant epilepsy. The multicenter study will test the safety of implanting interneurons into the hippocampus in patients with the disease. Future studies are planned to investigate the potential for these cells to restore normal excitatory-inhibitory balance.Continue reading→

The new center is seen as a worldwide bridge among scientists, researchers and physicians in their pursuit of new diagnostics and therapeutics to benefit patientsContinue reading→

Funding expands manufacturing readiness for Valley fever vaccine.  This follows Anivive’s $33MM NIAID contract for fungal vaccines
In total, Anivive has secured over $80MM in contracts and preordersContinue reading→

Report shows ASU is a major economic engine driving the state through investments, spinoffs, research, taxes paid by alumni and more.Continue reading→

Focuses genomic and proteomic lenses on three canine cancers
Continue reading→

New Leadership to Drive Expansion of Collaborative Initiatives and Fundraising Strategies at C-PathContinue reading→

Experimental, three-drug chemotherapy regimen didn’t improve survival rates for patients, but treatment might still prove helpful for a small subset of patients.Continue reading→

Financing Led by Evidity Health Capital Continue reading→

XLR8 PBC is an 8-day intensive program for scale-ready (series A/B) companies seeking the capital, experience, and industry validation to move to the next level. The program emphasizes finding the right capital at the right time, growth-stage executive matchmaking, and corporate partnerships to validate market fit. With resources like access to innovative collision spaces, student analysts, and a robust ecosystem, XLR8 is dedicated to enhancing the growth potential of scale-ups.Continue reading→